Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer

Thyroid

Volumn 24, Issue 5, 2014, Pages 918-922

  Blevins, Dean P ^a,b   Dadu, Ramona ^b,c   Hu, Mimi ^b   Baik, Christina ^d   Balachandran, Diwakar ^b   Ross, William ^b   Gunn, Brandon ^b   Cabanillas, Maria E ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; DEXAMETHASONE; LENVATINIB; SORAFENIB; SUNITINIB; THYROGLOBULIN; THYROTROPIN; 4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANILIDE; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NEW DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; ASPIRATION PNEUMONIA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS FISTULA; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HUMAN; LYMPH VESSEL METASTASIS; MALE; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; STERNOTOMY; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TUMOR INVASION; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; EPIDEMIOLOGY; ESOPHAGEAL FISTULA; FATALITY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; RESPIRATORY TRACT FISTULA; THYROID NEOPLASMS; THYROIDECTOMY; TRACHEOESOPHAGEAL FISTULA; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANGIOGENESIS INHIBITORS; ANILIDES; COMBINED MODALITY THERAPY; DRUGS, INVESTIGATIONAL; ESOPHAGEAL FISTULA; FATAL OUTCOME; HUMANS; INDOLES; MALE; MIDDLE AGED; NECK DISSECTION; PHENYLUREA COMPOUNDS; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RESPIRATORY TRACT FISTULA; RISK FACTORS; TEXAS; THYROID NEOPLASMS; THYROIDECTOMY; TRACHEOESOPHAGEAL FISTULA;

EID: 84901265163     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0598     Document Type: Article

References (25)

1. Siegel R, Ma J, Zou Z, Jemal A 2014 Cancer Statistics, CA Cancer J Clin 64:9-29.
2. Roman S, Lin R, Sosa JA 2006 Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142. (Pubitemid 44665646)
3. Gilliland FD,HuntWC,Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573.
4. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713.
5. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R 2011 Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666.
6. Sherman SI, Jarzab B, Cabanillas ME, Licitra L, Pacini F, Martins R, Robinson B, Ball DW, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP, Schlumberger M 2011 A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 29:5503 [Abstract].
7. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42. (Pubitemid 351931094)
8. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 11:962-972.
9. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
10. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
11. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595.
12. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268.
13. Sherman SI, Tuttle RM, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Doherty GM, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ 2009 NCCN Practice Guidelines in Oncology: Thyroid Carcinoma. J Natl Compr Canc Netw 1.2009.
14. Package insert sorafenib (Nexavar). Available at: Www .berlex.bayerhealthcare.com/html/products/pi/Nexavar-PI.pdf (accessed September 14, 2012).
15. Package insert sunitinib (Sutent). Available at: Www .pfizeroncology.com/ sites/pop/PDFs/uspi-sutent.pdf (accessed September 14, 2012).
16. Package insert vandetanib (Vandetanib). Available at: Www1.astrazeneca-us.com/pi/vandetanib.pdf (accessed September 14, 2012).
17. Package insert pazopanib (Votrient). Available at: Glaxo SmithKline. www.gsksource.com/gskprm/htdocs/documents/ VOTRIENT-PI-MG.PDF (accessed September 14, 2012)
18. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE 2008 Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:abstr 6025.
19. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA 2010 Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28:43-48.
20. Goodgame B, Veeramachaneni N, Patterson A, Govindan R 2008 Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J Thorac Oncol 3:1080-1081.
21. Gore E, Currey A, Choong N 2009 Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. J Thorac Oncol 4:1590-1591.
22. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE 2008 Phase I study of bevacizumab added to fluorouracil-And hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 26:1732-1741.
23. Basille D, Andrejak M, Bentayeb H, Kanaan M, Fournier C, Lecuyer E, Boutemy M, Garidi R, Douadi Y, Dayen C 2010 Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann Pharmacother 44:383-386.
24. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS 2009 Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74: 1083-1091.
25. Grossman TW, Wilson JF, Toohill RJ 1985 Delayed aerodigestive tract complications following combined therapy for thyroid cancer. Ann Otol Rhinol Laryngol 94: 505-508. (Pubitemid 16251275)